Veklury® (remdesivir)

Veklury (remdesivir) is authorized for a single 3‑day IV course to treat mild‑to‑moderate COVID‑19 in adults and pediatric patients (birth to <18 years) weighing ≥1.5 kg who are at high risk for progression to severe disease, and is not authorized for patients <1.5 kg or for uses outside the FDA‑approved indication. Approval requires a documented positive SARS‑CoV‑2 test, recorded weight to determine the age/weight‑based dosing regimen, documentation that the patient is high‑risk, record of administered dosing/duration (3 days), and prescriber attestation that applicable safety criteria have been reviewed and met.

"Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age and weighing at least 1."

Sign up to see full coverage criteria, indications, and limitations.